Archives

Abstract Number: 495 – Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm–‘2 Studies

Presenter: Anita D’Souza, MD, MSSession: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMADate & Time: Sunday, December 8, 2024 10:00 AM–10:15 AMLocation: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)Keywords: Daratumumab,...

Abstract Number: 494 – Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Presenter: Elena Zamagni, MDSession: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMADate & Time: Sunday, December 8, 2024 9:45 AM–10:00 AMLocation: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)Keywords: Teclistamab, MajesTEC-4,...

Abstract Number: 493 – Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Presenter: Marc S. Raab, M.D.Session: 654. Multiple Myeloma: Pharmacologic Therapies: Targeting BCMADate & Time: Sunday, December 8, 2024 9:30 AM–9:45 AMLocation: Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)Keywords: Teclistamab, CD38,...

Abstract Number: 490 – A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Presenter: Evangelos Terpos, MD, PhDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical PracticeDate & Time: Sunday, December 8, 2024 10:15 AM–10:30 AMLocation: Pacific...

Abstract Number: 489 – Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Presenter: Noemi Puig, PhDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Cellular and Molecular Profiling of Multiple Myeloma: Implications for Clinical PracticeDate & Time: Sunday, December 8, 2024 10:00 AM–10:15 AMLocation: Pacific Ballroom...

« Older Entries

Next Entries »

Abstract Number: 495 – Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm–‘2 Studies

Abstract Number: 493 – Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Abstract Number: 490 – A Novel Prognostic System Based on Circulating Tumor Cells for Newly Diagnosed Multiple Myeloma

Abstract Number: 489 – Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis

Recent Posts

Recent Comments

Categories

Meta